A carregar...

Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia

BACKGROUND: We evaluated BCR-ABL1 kinetics in patients treated with nilotinib and analyzed whether a dynamic model of changes in BCR-ABL1 levels over time could be used to predict long-term responses. METHODS: Patients from the nilotinib registration trial (CAMN107A2101; registered at http://www.cli...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Stein, Andrew M, Martinelli, Giovanni, Hughes, Timothy P, Müller, Martin C, Beppu, Lan, Gottardi, Enrico, Branford, Susan, Soverini, Simona, Woodman, Richard C, Hochhaus, Andreas, Kim, Dong-Wook, Saglio, Giuseppe, Radich, Jerald P
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2013
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3646679/
https://ncbi.nlm.nih.gov/pubmed/23547655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-173
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Internet

https://ncbi.nlm.nih.gov/pmc/articles/PMC3646679/
https://ncbi.nlm.nih.gov/pubmed/23547655
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1471-2407-13-173
Cannot write session to /tmp/vufind_sessions/sess_91c1u3feld8d8kg35ivteuvul4